With sparse R&D prospects, Incyte bets $900M on MorphoSys' CAR-T rival tafasitamab
Having suffered a string of pipeline setbacks in recent years, Incyte is reinvigorating its R&D prospects with a pact to develop and market MorphoSys’ anti-CD19 antibody tafasitamab, a drug being primed as an alluring alternative to the existing CAR-T therapies Kymriah and Yescarta in patients with a common, treatment-resistant form of non-Hodgkin’s lymphoma.
Under the deal, MorphoSys and Incyte will co-commercialize tafasitamab in the United States, while Incyte has exclusive commercialization rights outside the region. For these rights, Incyte is giving MorphoSys an upfront payment of $750 million as well as making an equity investment worth $150 million in the company. The German drugmaker is also eligible to receive milestone payments of up to $1.1 billion, in addition to royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.